• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

腋窝手术对非转移性乳腺癌有治疗益处吗?一项监测、流行病学和最终结果(SEER)队列数据库研究。

Is There a Therapeutic Benefit of Axillary Surgery in Non-Metastatic Breast Cancer? A SEER Cohort Database Study.

作者信息

Sabah Jonathan, Marouk Alexis, Molière Sébastien, Lodi Massimo

机构信息

Breast Reconstructive and Plastic Surgery, Louis Pasteur Hospital, 68000 Colmar, France.

Assistance Publique-Hôpitaux de Paris (APHP), 75610 Paris, France.

出版信息

J Clin Med. 2025 Sep 6;14(17):6314. doi: 10.3390/jcm14176314.

DOI:10.3390/jcm14176314
PMID:40944072
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC12429030/
Abstract

Axillary lymph node biopsy (ALND) has traditionally been considered the gold standard for axillary staging and treatment in clinically node-positive breast cancer patients. However, in patients with nodal disease, the therapeutic benefit of ALND is uncertain. This study, based on a large cohort, aims to evaluate breast cancer-specific survival depending on the extent of axillary surgery in non-metastatic breast cancer using real-world data from the Surveillance, Epidemiology, and End Results (SEER) database. This retrospective cohort study comprised 825,240 patients diagnosed with breast cancer between 2000 and 2020. ALND was associated with a worse survival outcome in pN0 and pN1 populations (respectively, hazard ratio [HR] 1.16; 95% confidence interval [CI] 1.12-1.2; < 0.001 and HR 1.38; 95%CI 1.3-1.46; < 0.001). In pN2 and pN3 populations, there was ~4.3% relative reduction in the hazard of breast cancer-related death for each additional node removed; and higher positive-to-removed lymph node ratio was associated with worse prognosis (HR 3.450; 95%CI 2.99-3.98; < 0.001). SLNB is associated with significantly better specific survival compared to ALND in negative/low axillary involvement, in higher axillary involvement categories extensive axillary surgery was associated with better prognosis.

摘要

传统上,腋窝淋巴结活检(ALND)一直被视为临床淋巴结阳性乳腺癌患者腋窝分期和治疗的金标准。然而,对于有淋巴结疾病的患者,ALND的治疗益处尚不确定。本研究基于一个大型队列,旨在利用监测、流行病学和最终结果(SEER)数据库中的真实世界数据,评估非转移性乳腺癌患者腋窝手术范围对乳腺癌特异性生存的影响。这项回顾性队列研究纳入了2000年至2020年间确诊为乳腺癌的825240例患者。在pN0和pN1人群中,ALND与较差的生存结果相关(风险比[HR]分别为1.16;95%置信区间[CI]为1.12 - 1.2;P < 0.001和HR 1.38;95%CI为1.3 - 1.46;P < 0.001)。在pN2和pN3人群中,每多切除一个淋巴结,乳腺癌相关死亡风险相对降低约4.3%;且阳性淋巴结与切除淋巴结的比例越高,预后越差(HR 3.450;95%CI为2.99 - 3.98;P < 0.001)。在腋窝转移阴性/低转移的情况下,与ALND相比,前哨淋巴结活检(SLNB)与显著更好的特异性生存相关,在腋窝转移较高的类别中,广泛腋窝手术与较好的预后相关。

https://cdn.ncbi.nlm.nih.gov/pmc/blobs/66b9/12429030/8952a8e00b5a/jcm-14-06314-g002.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/66b9/12429030/f5bb00974dfe/jcm-14-06314-g001.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/66b9/12429030/294956572508/jcm-14-06314-g0A1.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/66b9/12429030/8952a8e00b5a/jcm-14-06314-g002.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/66b9/12429030/f5bb00974dfe/jcm-14-06314-g001.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/66b9/12429030/294956572508/jcm-14-06314-g0A1.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/66b9/12429030/8952a8e00b5a/jcm-14-06314-g002.jpg

相似文献

1
Is There a Therapeutic Benefit of Axillary Surgery in Non-Metastatic Breast Cancer? A SEER Cohort Database Study.腋窝手术对非转移性乳腺癌有治疗益处吗?一项监测、流行病学和最终结果(SEER)队列数据库研究。
J Clin Med. 2025 Sep 6;14(17):6314. doi: 10.3390/jcm14176314.
2
Axillary treatment for operable primary breast cancer.可手术原发性乳腺癌的腋窝治疗
Cochrane Database Syst Rev. 2017 Jan 4;1(1):CD004561. doi: 10.1002/14651858.CD004561.pub3.
3
Trends in Surgical Axillary Staging and Clinical Outcomes Among Breast Cancer Patients With Neoadjuvant Therapy: A Population-Based Cohort Study.接受新辅助治疗的乳腺癌患者腋窝手术分期及临床结局的趋势:一项基于人群的队列研究
Clin Breast Cancer. 2025 Jul;25(5):e525-e532.e3. doi: 10.1016/j.clbc.2025.02.001. Epub 2025 Feb 6.
4
Changing practice patterns in axillary management for patients with node-positive breast cancer towards increased use of sentinel lymph node biopsy-alone after neoadjuvant chemotherapy: results of a survey (MF17-01) among Turkish surgeons.新辅助化疗后,针对淋巴结阳性乳腺癌患者的腋窝处理模式发生变化,更多地采用仅前哨淋巴结活检:一项针对土耳其外科医生的调查(MF17 - 01)结果
Langenbecks Arch Surg. 2025 Jun 16;410(1):196. doi: 10.1007/s00423-025-03767-9.
5
Positron emission tomography (PET) and magnetic resonance imaging (MRI) for the assessment of axillary lymph node metastases in early breast cancer: systematic review and economic evaluation.正电子发射断层扫描(PET)和磁共振成像(MRI)在早期乳腺癌腋窝淋巴结转移评估中的应用:系统评价和经济评估。
Health Technol Assess. 2011 Jan;15(4):iii-iv, 1-134. doi: 10.3310/hta15040.
6
Sentinel lymph node biopsy followed by lymph node dissection for localised primary cutaneous melanoma.前哨淋巴结活检后行局部原发性皮肤黑色素瘤淋巴结清扫术。
Cochrane Database Syst Rev. 2015 May 16;2015(5):CD010307. doi: 10.1002/14651858.CD010307.pub2.
7
The Role of Axillary Lymph Node Dissection in Breast Cancer Patients With Residual Nodal Disease After Receiving Neoadjuvant Chemotherapy.腋窝淋巴结清扫术在接受新辅助化疗后仍有残留淋巴结疾病的乳腺癌患者中的作用。
Breast Cancer (Auckl). 2025 Aug 10;19:11782234251352996. doi: 10.1177/11782234251352996. eCollection 2025.
8
Outcomes and Trends in Axillary Management of Stage cN3b Breast Cancer Patients.cN3b期乳腺癌患者腋窝处理的结局与趋势
Ann Surg Oncol. 2025 Mar;32(3):2070-2078. doi: 10.1245/s10434-024-16630-w. Epub 2024 Dec 14.
9
Trends in Axillary Lymph Node Dissection After Mastectomy Among Patients With Limited Nodal Burden.淋巴结负荷有限的患者乳房切除术后腋窝淋巴结清扫的趋势
JAMA Netw Open. 2025 Feb 3;8(2):e2459692. doi: 10.1001/jamanetworkopen.2024.59692.
10
American College of Surgeons Operative Standards and Breast Cancer Outcomes.美国外科医师学会手术标准与乳腺癌结局
JAMA Netw Open. 2024 Nov 4;7(11):e2446345. doi: 10.1001/jamanetworkopen.2024.46345.

本文引用的文献

1
Feasibility of sentinel lymph node biopsy omission after integration of F-FDG dedicated lymph node PET in early breast cancer: a prospective phase II trial.早期乳腺癌中整合F-FDG专用淋巴结PET后省略前哨淋巴结活检的可行性:一项前瞻性II期试验
Cancer Biol Med. 2022 Jul 21;19(7). doi: 10.20892/j.issn.2095-3941.2022.0085.
2
Predicting pathologic ≥N2 disease in women with breast cancer.预测乳腺癌女性患者的病理分期≥N2疾病
NPJ Breast Cancer. 2025 May 22;11(1):46. doi: 10.1038/s41523-025-00757-4.
3
How can we optimize the surgical management of the axilla in breast cancer since the MonarchE trial?
自MonarchE试验以来,我们如何优化乳腺癌腋窝的手术管理?
Breast Cancer Res Treat. 2025 Jul;212(1):13-21. doi: 10.1007/s10549-025-07642-5. Epub 2025 May 6.
4
Sentinel Lymph Node Biopsy in Early-Stage Breast Cancer: ASCO Guideline Update.早期乳腺癌前哨淋巴结活检:美国临床肿瘤学会指南更新
J Clin Oncol. 2025 May 10;43(14):1720-1741. doi: 10.1200/JCO-25-00099. Epub 2025 Apr 10.
5
Axillary Surgery in Breast Cancer - Primary Results of the INSEMA Trial.乳腺癌腋窝手术——INSEMA试验的初步结果
N Engl J Med. 2025 Mar 13;392(11):1051-1064. doi: 10.1056/NEJMoa2412063. Epub 2024 Dec 12.
6
A phase III trial of adjuvant ribociclib plus endocrine therapy versus endocrine therapy alone in patients with HR-positive/HER2-negative early breast cancer: final invasive disease-free survival results from the NATALEE trial.一项针对激素受体阳性/人表皮生长因子受体2阴性早期乳腺癌患者的辅助性瑞博西尼联合内分泌治疗与单纯内分泌治疗的III期试验:NATALEE试验的最终无侵袭性疾病生存期结果
Ann Oncol. 2025 Feb;36(2):149-157. doi: 10.1016/j.annonc.2024.10.015. Epub 2024 Oct 21.
7
Abemaciclib Therapy Using the MonarchE Criteria Results in Large Numbers of Excess Axillary Node Clearances-Time to Pause and Reflect?使用MonarchE标准的阿贝西利治疗导致大量额外的腋窝淋巴结清扫——是时候暂停并反思了?
Cancers (Basel). 2024 Sep 4;16(17):3072. doi: 10.3390/cancers16173072.
8
Axillary Surgery for Breast Cancer in 2024.2024年乳腺癌腋窝手术
Cancers (Basel). 2024 Apr 23;16(9):1623. doi: 10.3390/cancers16091623.
9
Omitting Axillary Dissection in Breast Cancer with Sentinel-Node Metastases.省略腋窝清扫术治疗前哨淋巴结转移乳腺癌。
N Engl J Med. 2024 Apr 4;390(13):1163-1175. doi: 10.1056/NEJMoa2313487.
10
Is routine axillary lymph node dissection needed to tailor systemic treatments for breast cancer patients in the era of molecular oncology? A position paper of the Italian National Association of Breast Surgeons (ANISC).在分子肿瘤学时代,是否需要常规行腋窝淋巴结清扫术来制定乳腺癌患者的全身治疗方案?意大利乳腺外科医师协会(ANISC)的立场文件。
Eur J Surg Oncol. 2024 Feb;50(2):107954. doi: 10.1016/j.ejso.2024.107954. Epub 2024 Jan 6.